Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DADare Bioscience, Inc. logo

Dare Bioscience, Inc. (DARE)

NASDAQ · Currency in USD
$0.65 ▼ -0.01 (-0.89%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.68 ▲ +0.04 (+5.56%)
After hours: Oct 23, 5:28 PM ET

Summary

Previous Close
$0.65
Open
$0.64
Day's Range
$0.64 – $0.67
52 Week Range
$0.63 – $3.78
Volume
56,273
Avg. Volume
411,712
Market Cap
$9.68M
Beta (5Y Monthly)
1.01
PE Ratio (TTM)
--
EPS (TTM)
-$0.74
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1.00

Profile: Dare Bioscience, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
23
CEO
Sabrina Martucci Johnson

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.14 · Revenue est. $2.02M
DateEst.Actual
Aug 13, 2026-$0.30-$0.20Beat
May 14, 2026-$0.33-$0.20Beat
Mar 26, 2026-$0.24-$0.02Beat
Nov 13, 2025-$0.33-$0.28Beat
Aug 14, 2025-$0.55-$0.45Beat
May 13, 2025-$0.63-$0.50Beat

Analyst view

Consensus price target
$1.00 ▲ +54.8%
Range $1.00 – $1.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on DARE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.